Tr1X Announces Leadership Transition: David de Vries Appointed CEO, Bill Lis Moves to Executive Chairman Role

Tr1X, a clinical-stage biopharmaceutical company focused on developing allogeneic engineered Treg and CAR-Treg cell therapies, has announced a leadership transition effective June 1, 2025. David de Vries, co-founder and Chief Operating Officer, will take over as CEO from Bill Lis, who will become Executive Chairman of the Board. The succession plan is supported by The Column Group, a key investor. Mr. de Vries brings significant experience from his previous roles at Arine and Proteus Digital Health. Under his leadership, Tr1X aims to advance their clinical-stage programs, including TRX103 and TRX319, with ongoing studies expected to provide additional data later this year and early next year. Tr1X's therapies strive to reset the immune system in patients, potentially curing autoimmune and inflammatory diseases, thereby transforming the current treatment paradigms.